Literature DB >> 29308327

Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.

Maria Carmen Ochoa1,2,3, Luna Minute1,2, Ascensión López4,5, Elisabeth Pérez-Ruiz1,2, Celia Gomar1,2, Marcos Vasquez1,2, Susana Inoges4,5, Iñaki Etxeberria1,2, Inmaculada Rodriguez1,2,3, Saray Garasa1,2, Jan-Peter Andreas Mayer6, Peter Wirtz6, Ignacio Melero1,2,4,3, Pedro Berraondo1,2,3.   

Abstract

Enhancement of antibody-dependent cellular cytotoxicity (ADCC) may potentiate the antitumor efficacy of tumor-targeted monoclonal antibodies. Increasing the numbers and antitumor activity of NK cells is a promising strategy to maximize the ADCC of standard-of-care tumor-targeted antibodies. For this purpose, we have preclinically tested a recombinant chimeric protein encompassing the sushi domain of the IL15Rα, IL-15, and apolipoprotein A-I (Sushi-IL15-Apo) as produced in CHO cells. The size-exclusion purified monomeric fraction of this chimeric protein was stable and retained the IL-15 and the sushi domain bioactivity as measured by CTLL-2 and Mo-7e cell proliferation and STAT5 phosphorylation in freshly isolated human NK and CD8+ T cells. On cell cultures, Sushi-IL15-Apo increases NK cell proliferation and survival as well as spontaneous and antibody-mediated cytotoxicity. Scavenger receptor class B type I (SR-B1) is the receptor for ApoA-I and is expressed on the surface of tumor cells. SR-B1 can adsorb the chimeric protein on tumor cells and can transpresent IL-15 to NK and CD8+ T cells. A transient NK-humanized murine model was developed to test the increase of ADCC attained by the chimeric protein in vivo. The EGFR+ human colon cancer cell line HT-29 was intraperitoneally inoculated in immune-deficient Rag2-/-γc-/- mice that were reconstituted with freshly isolated PBMCs and treated with the anti-EGFR mAb cetuximab. The combination of the Sushi-IL15-Apo protein and cetuximab reduced the number of remaining tumor cells in the peritoneal cavity and delayed tumor engraftment in the peritoneum. Furthermore, Sushi-IL15-Apo increased the anti-tumor effect of a murine anti-EGFR mAb in Rag1-/- mice bearing subcutaneous MC38 colon cancer transfected to express EGFR. Thus, Sushi-IL15-Apo is a potent tool to increase the number and the activation of NK cells to promote the ADCC activity of antibodies targeting tumor antigens.

Entities:  

Keywords:  NK cell; antibody-dependent cellular cytotoxicity; apolipoprotein A-I; cetuximab; interleukin 15; scavenger receptor class B type I

Year:  2017        PMID: 29308327      PMCID: PMC5749662          DOI: 10.1080/2162402X.2017.1393597

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  26 in total

1.  The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Authors:  Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2015-09-30       Impact factor: 12.531

2.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

Review 3.  Interleukin-2 toxicity.

Authors:  J P Siegel; R K Puri
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

4.  Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.

Authors:  Erwan Mortier; Agnès Quéméner; Patricia Vusio; Inken Lorenzen; Yvan Boublik; Joachim Grötzinger; Ariane Plet; Yannick Jacques
Journal:  J Biol Chem       Date:  2005-11-11       Impact factor: 5.157

5.  The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15.

Authors:  G Kurys; Y Tagaya; R Bamford; J A Hanover; T A Waldmann
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

6.  NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.

Authors:  Esther Moga; Eva Alvarez; Elisabet Cantó; Silvia Vidal; José Luis Rodríguez-Sánchez; Jorge Sierra; Javier Briones
Journal:  Exp Hematol       Date:  2007-10-23       Impact factor: 3.084

Review 7.  Interleukin-15 in gene therapy of cancer.

Authors:  Maria C Ochoa; Guillermo Mazzolini; Sandra Hervas-Stubbs; Miguel F de Sanmamed; Pedro Berraondo; Ignacio Melero
Journal:  Curr Gene Ther       Date:  2013-02       Impact factor: 4.391

8.  Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.

Authors:  Marie Vincent; Anne Bessard; Denis Cochonneau; Géraldine Teppaz; Véronique Solé; Mike Maillasson; Stéphane Birklé; Laure Garrigue-Antar; Agnès Quéméner; Yannick Jacques
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

Review 9.  Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR-B1.

Authors:  Marcos Vasquez; Inês Simões; Marta Consuegra-Fernández; Fernando Aranda; Francisco Lozano; Pedro Berraondo
Journal:  Eur J Immunol       Date:  2017-06-12       Impact factor: 5.532

10.  Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.

Authors:  Maria C Ochoa; Jessica Fioravanti; Erwin H Duitman; Jose Medina-Echeverz; Asis Palazon; Ainhoa Arina; Juan Dubrot; Carlos Alfaro; Aizea Morales-Kastresana; Oihana Murillo; Sandra Hervas-Stubbs; Jesus Prieto; Pedro Berraondo; Ignacio Melero
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more
  6 in total

Review 1.  Cytokines in clinical cancer immunotherapy.

Authors:  Pedro Berraondo; Miguel F Sanmamed; María C Ochoa; Iñaki Etxeberria; Maria A Aznar; José Luis Pérez-Gracia; María E Rodríguez-Ruiz; Mariano Ponz-Sarvise; Eduardo Castañón; Ignacio Melero
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

Review 2.  Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis.

Authors:  Anahid Jewett; Janko Kos; Kawaljit Kaur; Tahmineh Safaei; Christine Sutanto; Wuyang Chen; Paul Wong; Artin Keshishian Namagerdi; Changge Fang; Yuman Fong; Meng-Wei Ko
Journal:  Mol Ther Oncolytics       Date:  2019-11-29       Impact factor: 7.200

3.  Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.

Authors:  Sigrid P Dubois; Milos D Miljkovic; Thomas A Waldmann; Kevin C Conlon; Thomas A Fleisher; Stefania Pittaluga; Jennifer Hsu-Albert; Bonita R Bryant; Michael N Petrus; Liyanage P Perera; Jürgen R Müller; Joanna H Shih
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

Review 4.  Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity.

Authors:  Alberto Mendoza-Valderrey; Maite Alvarez; Andrea De Maria; Kim Margolin; Ignacio Melero; Maria Libera Ascierto
Journal:  Cells       Date:  2022-10-06       Impact factor: 7.666

5.  Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.

Authors:  Alessandro Ottaiano; Stefania Scala; Nicola Normanno; Maria Napolitano; Monica Capozzi; Anna Maria Rachiglio; Cristin Roma; Anna Maria Trotta; Crescenzo D'Alterio; Luigi Portella; Carmela Romano; Antonino Cassata; Rossana Casaretti; Lucrezia Silvestro; Anna Nappi; Salvatore Tafuto; Antonio Avallone; Alfonso De Stefano; Mario Tamburini; Carmine Picone; Antonella Petrillo; Francesco Izzo; Raffaele Palaia; Vittorio Albino; Alfonso Amore; Andrea Belli; Ugo Pace; Massimiliano Di Marzo; Paolo Chiodini; Gerardo Botti; Gianfranco De Feo; Paolo Delrio; Guglielmo Nasti
Journal:  BMC Cancer       Date:  2019-09-09       Impact factor: 4.430

6.  Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer.

Authors:  Thomas A Waldmann; Milos D Miljkovic; Kevin C Conlon
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.